ABBVIE INC.

ABBV Stock Report Card

Today's performance

61%

Performance

Score:

12/100

ABBV returned -12.02% in the last 12 months. Based on SPY's performance of -8.69%, its performance is below average giving it a score of 11 of 100.

Analyst Price Targets

Score:

68/100

20 analysts offer 12-month price targets for ABBV. Together, they have an average target of 157.86, the most optimistic target put ABBV at 200 within 12-months and the most pessimistic has ABBV at 127. These analyst ratings are from our partners at Financial Modeling Prep (https://site.financialmodelingprep.com/) and Alpha Vantage (https://www.alphavantage.co/).

Sentiment

Score:

71/100

ABBV had a bullish sentiment score of 70.98% across Twitter and StockTwits over the last 12 months. It had an average of 187.98 posts, 3,232.36 comments, and 19,769.57 likes per day.

Technicals

Score:

10/100

ABBV receives a 10 of 100 based on 14 indicators. 0 are bullish, 12 are bearish.

Earnings

Score:

100/100

ABBV has missed earnings 0 times in the last 20 quarters.

Profit

Score:

61/100

Out of the last 20 quarters, ABBV has had 18 profitable quarters and has increased their profits year over year on 5 of them.

Volatility

Score:

47/100

ABBV has had a lower than average amount of volatility over the last 12 months giving it a score of 46 of 100.

Dividend

Score:

91/100

ABBV's most recent dividend was $0.98 per share, based on a share price of $133.59. It was a payout ratio of 77.21% compared to their total earnings.

ABBVIE INC. Summary

New York Stock Exchange / ABBV

Healthcare

Drug Manufacturers—General

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Pluto is a technology provider that provides you with information, software, and automation tools for the purpose of investment education, but it does not make investment recommendations of securities, investment strategies, or account types, either in general or individualized for you or any other subscriber. If you want to receive individualized investment advice, you should consult with your own financial adviser. Pluto also does not provide you with legal, tax, or accounting advice. You agree that you understand that Pluto is not an investment adviser or a broker-dealer and does not have a fiduciary duty to you or a duty to act in your best interests. Pluto can help you back-test the historical performance of strategies that you create, but it does not recommend strategies and reminds you that the historical performance of a strategy is not a reliable predictor of future results for that strategy. Pluto uses third-party information, for example, about securities market data, that it reasonably believes to be reliable, but it does not warrant that the information is complete, accurate, or up-to-date, and as discussed further below, Pluto does not provide any warranty of merchantability or warranty for a particular purpose for that third-party market data or other information. Investing involves risk, including the risk of loss, and you should not use the Pluto technology in connection with investments unless you are able to and intend to evaluate the technology and the risks and make your own self-directed investment decisions.

Power up your portfolio

Build a portfolio of your favorite stocks

Pluto makes it easy to build investing strategies and automate your portfolio

See how

Checkout Similar Companies

ABBV scored highly on our reportcard. Here are some similar companies and how they performed.

Johnson & Johnson

$JNJ Stock Report Card

Pfizer Inc.

$PFE Stock Report Card

AstraZeneca PLC

$AZN Stock Report Card

Novartis AG

$NVS Stock Report Card

UNITEDHEALTH GROUP INCORPORATED (Delaware)

$UNH Stock Report Card

Eli Lilly & Co.

$LLY Stock Report Card

Novo-Nordisk A/S

$NVO Stock Report Card

Merck & Co., Inc.

$MRK Stock Report Card

View all stock report cards

Los Angeles, CA

Pluto is not a broker-dealer, investment adviser or member of FINRA. Securities offered by Alpaca Securities LLC (“Alpaca Securities”). Alpaca Securities is a member of FINRA and the Securities Investor Protection Corporation.

Alpaca Securities, LLC (“Alpaca Securities”) is not responsible for and is not providing the technology and services you receive from us to access and manage your brokerage account with Alpaca Securities. You firmly agree to hold Alpaca and its affiliates, owners, directors, employees, clearing firm and agents harmless for any loss or damage arising from the use of or unavailability of the technology and services that we are providing.

The content on this website is for informational purposes only. Pluto does not recommend any specific securities or investment strategies. Investing involves risk & investments may lose value, including the loss of principal. Past performance does not guarantee future results. Investors should consider their investment objectives and risks carefully before investing.